Patent Assignment
Reel/Frame 068236/0418
Security Interest
Recorded: 2024-08-09
Pages: 14
Assignor
ARCUTIS BIOTHERAPEUTICS, INC.
Executed: 2024-08-09
Assignee
SLR INVESTMENT CORP.
500 PARK AVENUE, 3RD FLOOR, NEW YORK, NEW YORK, 10022
Covered Properties
(29)
Pharmaceutical Compositions of Roflumilast and Solvents Capable of Dissolving High Amounts of the Drug
Inhibition of Crystal Growth of Roflumilast
Compositions and Methods for Deep Dermal Drug Delivery
Application:
18/037,316 →
Publication:
US 2023/0414511
Topical Roflumilast Formulation Having Improved Delivery and Plasma Half- Life
Method and Formulation for Improving Roflumilast Skin Penetration Lag Time
Application:
18/345,692 →
Publication:
US 2023/0346689
Method and Formulation for Improving Roflumilast Skin Penetration Lag Time
Application:
18/345,760 →
Publication:
US 2023/0346690
Method and Formulation for Improving Roflumilast Skin Penetration Lag Time
Application:
18/345,732 →
Publication:
US 2023/0338275
Laureth-4 Containing Topical Formulations
Topical Roflumilast Formulation Having Antifungal Properties
Self-Preserving Topical Pharmaceutical Compositions Comprising Diethylene Glycol Monoethyl Ether
Application:
17/887,798 →
Publication:
US 2023/0310345
Self-Preserving Topical Pharmaceutical Compositions Comprising Diethylene Glycol Monoethyl Ether
Application:
18/198,684 →
Publication:
US 2023/0310346
Compositions and Methods for Deep Dermal Drug Delivery
Topical Roflumilast Aerosol Foams
Application:
17/821,051 →
Publication:
US 2023/0201177
Topical Aerosol Foams
Application:
18/146,112 →
Publication:
US 2023/0190651
Stable Formulations of SHR0302
Pharmaceutical Compositions of Spironolactone for Deep Dermal Drug Delivery
Application:
17/984,405 →
Publication:
US 2023/0143609
Pharmaceutical Compositions of Roflumilast in Aqueous Blends of Water-Miscible, Pharmaceutically Acceptable Solvents
Application:
18/057,777 →
Publication:
US 2023/0091358
Treatment of Skin Conditions Using High Krafft Temperature Anionic Surfactants
Application:
17/703,543 →
Publication:
US 2022/0211730
Method for Reducing Side Effects from Administration of Phosphodiesterase-4 Inhibitors
Method for Reducing Side Effects from Administration of Phosphodiesterase-4 Inhibitors
Application:
18/745,005 →
Publication:
US 2025/0049771
Topical Roflumilast Formulation Having Improved Delivery and Plasma Half- Life
Treatment of Skin Conditions Using High Krafft Temperature Anionic Surfactants
Application:
18/627,861 →
Publication:
US 2024/0261308
Inhibition of Crystal Growth of Roflumilast
Method for Reducing Side Effects from Administration of Phosphodiesterase-4 Inhibitors
Roflumilast Formulations with an Improved Pharmacokinetic Profile
Roflumilast Formulations with an Improved Pharmacokinetic Profile
Topical Roflumilast Formulation Having Improved Delivery and Plasma Half- Life
Laureth-4 Containing Topical Formulations
Topical Roflumilast Formulation Having Antifungal Properties
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Oct 31, 2022
From: OSBORNE, DAVID W.; TOFIG, BABAK N.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 061599/0734 →
Assignment of Assignor's Interest
Feb 3, 2023
From: OSBORNE, DAVID W.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 062586/0962 →
Assignment of Assignor's Interest
May 2, 2023
From: BRINKMAN, HERBERT R.; CARBOL, JASON MICHAEL
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 063505/0216 →
Change of Name
Jun 29, 2023
From: ARCUTIS, INC.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 064165/0630 →
Assignment of Assignor's Interest
Jun 29, 2023
From: OSBORNE, DAVID W.
To: ARCUTIS, INC.
Reel/Frame 064118/0105 →
Assignment of Assignor's Interest
Aug 7, 2023
From: OSBORNE, DAVID W.; BERK, DAVID
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 064508/0162 →
Assignment of Assignor's Interest
Aug 18, 2023
From: OSBORNE, DAVID W.; TOFIG, BABAK N.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 064637/0365 →
Assignment of Assignor's Interest
Oct 13, 2023
From: OSBORNE, DAVID
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 065210/0795 →
Assignment of Assignor's Interest
Oct 13, 2023
From: OSBORNE, DAVID
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 065207/0788 →
Assignment of Assignor's Interest
Nov 15, 2023
From: OSBORNE, DAVID W.; TOFIG, BABAK N.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 065574/0955 →
Assignment of Assignor's Interest
Nov 15, 2023
From: OSBORNE, DAVID W.; TOFIG, BABAK N.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 065573/0529 →
Assignment of Assignor's Interest
Dec 15, 2023
From: OSBORNE, DAVID W.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 065886/0483 →
Assignment of Assignor's Interest
Dec 28, 2023
From: OSBORNE, DAVID W.; TOFIG, BABAK N.; WATANABE, FRANK
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 065971/0974 →
Assignment of Assignor's Interest
Feb 19, 2024
From: OSBORNE, DAVID W., SR.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 066490/0527 →
Assignment of Assignor's Interest
Feb 20, 2024
From: OSBORNE, DAVID W.; TOFIG, BABAK N.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 066496/0714 →
Change of Name
Feb 28, 2024
From: ARCUTIS, INC.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 066701/0639 →
Assignment of Assignor's Interest
Feb 28, 2024
From: OSBORNE, DAVID W.
To: ARCUTIS, INC.
Reel/Frame 066592/0983 →
Assignment of Assignor's Interest
Mar 1, 2024
From: BERK, DAVID REUBEN; BURNETT, PATRICK EUGENE; KATO, SAORI; OSBORNE, DAVID W.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 066758/0589 →
Change of Name
Mar 6, 2024
From: ARCUTIS, INC.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 066742/0412 →
Assignment of Assignor's Interest
Mar 6, 2024
From: OSBORNE, DAVID W.
To: ARCUTIS, INC.
Reel/Frame 066662/0184 →
Assignment of Assignor's Interest
Mar 19, 2024
From: OSBORNE, DAVID W.
To: ARCUTIS, INC.
Reel/Frame 066821/0437 →
Change of Name
Mar 19, 2024
From: ARCUTIS, INC.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 066821/0809 →
Assignment of Assignor's Interest
May 17, 2024
From: OSBORNE, DAVID W.
To: ARCUTIS, INC.
Reel/Frame 067446/0463 →
Change of Name
May 17, 2024
From: ARCUTIS, INC.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 067456/0235 →
Assignment of Assignor's Interest
May 29, 2024
From: OSBORNE, DAVID W.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 067546/0682 →